Ibrutinib plus RCHOP versus RCHOP only in young patients with activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL): A cost-effectiveness analysis
Last Updated: Wednesday, February 14, 2024
Data from a recent cost-effectiveness analysis showed that for patients age 60 and younger with activated B-cell–like DLBCL, treatment with I-RCHOP (RCHOP + ibrutinib) was more cost-effective, with greater quality-adjusted life years (QALY; 15.48 vs 14.25 years) and an incremental cost-effectiveness ratio of CAD 34,111.45/QALY compared to RCHOP only.
Advertisement
News & Literature Highlights
